NeurologyLive®
@neurology_live
Followers
9K
Following
8K
Media
6K
Statuses
40K
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments
United States
Joined July 2018
🚀 Big news: The new NeurologyLive website is here! Enjoy faster browsing, streamlined access, and bite-sized shorts to stay on top of neurology updates. Explore the upgrade today: https://t.co/ueeQYlOr7F
0
1
2
Our coverage of #AES2025 continues! Here are some of the notable studies and research we dove into: 🔎 Understanding the Mechanism and Rationale of Azetukalner to Treat Focal Epilepsy: Christopher Kenney, MD, FAAN - https://t.co/xKskjBhgOs 📉 Gene Therapy ETX101 Demonstrates
0
0
0
At #AES2025, Christopher Kenney, CMO at @XenonPharma, sat down to discuss the mechanism and rationale🧪 behind azetukalner to treat patients with focal epilepsy 🧠 More on this agent's selective potassium channel activation:
neurologylive.com
The chief medical officer at Xenon Pharmaceuticals outlined why azetukalner’s selective potassium channel activation offers a different way to suppress hyperexcitable neuronal circuits in focal...
0
1
0
Thanks @neurology_live for sharing this important #epilepsy surgery research from the @PERCepilepsy Surgery Database! Congrats to my research scientist Avery Caraway for presenting this poster at #AES2025
🧠 New #AES2025 data: ~ 1 in 5 children evaluated for drug-resistant epilepsy surgery in the U.S. are not offered the procedure. Variability in candidacy decisions highlights the need for standardized evaluation. 🔎 Read more: https://t.co/sRDrQH8NaH
#Epilepsy #Neurology #Neuro
0
2
6
🧒🧠 New insights on caring for children with NF1: Early, evaluation is critical, especially with 20–40% developing PN that can affect function, appearance, and quality of life. Earlier treatment with MEK inhibitors are improving outcomes 📈 Read more:
neurologylive.com
F1 Diagnostic Criteria and Clinical Recognition
0
0
1
Softness. Fit. The right feel. But do your favorite pieces stay comfy after the first wash—or the tenth? At SHEIN, our fabrics are stretched, rubbed, steamed, and spun to test for lasting comfort and durability. Real quality is how pieces hold up over time, not just day one.
17
79
175
📣 Excited to present my poster today at #AES2025! Loved the discussions and feedback on my work in epilepsy research and MRI 🧠@AmEpilepsySoc Many thanks to my PIs, Dr. Loddenkemper, Dr. Pearl and our team!
0
3
14
First year at #AES2025! Presented one poster as first author and co-authored another. Grateful to my mentor @DrBenjaminCoxMD for his support and inspiration. #AES2025
#Neurology
#Epilepsy
@UABEpilepsy
1
2
5
So much inspiration and genuine connection at AES 2025! When friendships fuel the future of neural networks, incredible things happen for epilepsy research. #AES2025 #AES #Epilepsy #neuralnetwork #plasticity #brain #Neurology
0
3
10
📍 Today at AES Atlanta! Join Dr. Schuele at the Clinical Skills Workshop on Stereoencephalography — don’t miss this session if you’re interested in the latest in epilepsy science and clinical innovation. Check the meeting program for time and room details. #AES2025
0
1
3
Excited to present our work at the American Epilepsy Society Annual Meeting, highlighting genetic epilepsies involving SCAR15 and BRPF1‑related neurodevelopmental epilepsies. 🧬🧠👶🏻⚡️#AES2025 Grateful to my mentors and my team! @UChicago_Neuro @AmEpilepsySoc #neurotwitternetwork
2
2
6
Feeling inspired after Dr. @IngoHelbig's workshop on genetic testing in pediatric epilepsy at #AES2025. The progress in genomic sequencing is incredible. Privilege to learn from the best at @AmEpilepsySoc. Excited to be part of this future. 🧠
0
1
5
🧠 New #AES2025 data: ~ 1 in 5 children evaluated for drug-resistant epilepsy surgery in the U.S. are not offered the procedure. Variability in candidacy decisions highlights the need for standardized evaluation. 🔎 Read more: https://t.co/sRDrQH8NaH
#Epilepsy #Neurology #Neuro
neurologylive.com
A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.
0
0
3
At #AES2025, interim POLARIS Phase 1/2 data showed ETX101 achieved: 🔹 78% median seizure reduction at DL3 🔹 Significant gains in communication & cognitive development 🔹 Favorable safety with no treatment-related serious AEs 🔗 ➡️ https://t.co/CaW6hr0QGH
#Neurology #Epilepsy
neurologylive.com
The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment...
0
0
1
@neurology_live @NMNeurology @AmEpilepsySoc Grateful to @AmEpilepsySoc for funding the #GEAN network and for fostering so many great collaborations. Excited to announce our website is live
geneticepilepsyinadults.org
0
1
4
Epilepsy affects 50M+ globally and women face unique challenges balancing seizure control & reproductive health. Dr. Esther Bui shares insights from #AES2025 on optimizing care. 🧠💊 🔗 ➡️ https://t.co/SMJKqq5Yev
#Epilepsy #WomensHealth #Neurology #SeizureCare #BrainHealth
0
0
0
Presented at #AES2025, OV329 shows promise in phase 1: ✔️ Safe & well tolerated ✔️ 53% ↑ in long-interval intracortical inhibition ✔️ Stronger cortical inhibition than vigabatrin ✔️ ↑ medial parietal GABA levels Phase 2a trial planned for 2️⃣0️⃣2️⃣6️⃣ 🔗 ➡️
neurologylive.com
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
0
0
1
More #AES2025 News 📰 Data shows stiripentol may significantly reduce seizure burden in patients with Lennox-Gastaut Syndrome Key takeaways: ☑️ 81% median reduction in seizures ☑️ 36% achieved seizure freedom by day 120 🔗 ➡️ https://t.co/W06YjbH2i8
#Neurology #Epilepsy
neurologylive.com
A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.
0
0
2
Ahead of my keynote lecture on the #neurologic health effects of the #EV industry at the @BaptistHealthAR #Neuroscience Symposium, I spoke with @neurology_live about my work investigating air pollution, industrial toxins, & environmental inequality: https://t.co/1aUnjhJEzV
0
2
2
We're thrilled to welcome Dr. Peter Abdelmalik, who brings a decade of neurocritical care experience and a clear vision for strengthening acute neurology care at Baptist Health Brain & Spine Care.
Peter Abdelmalik, MD, joining Baptist Health Brain & Spine as #Director of Inpatient General #Neurology 🧠 Dr. Abdelmalik aims to build a dedicated inpatient service, elevate resident training, and strengthen APP/nursing collaboration 🔗 ➡️ https://t.co/pMtoXkA8xs
#Leadership
0
3
4